Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.300
-0.010 (-0.76%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Fate Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Fate Therapeutics stock have an average target of 4.10, with a low estimate of 2.00 and a high estimate of 7.00. The average target predicts an increase of 215.38% from the current stock price of 1.30.
Analyst Consensus: Buy
* Price targets were last updated on Oct 31, 2025.
Analyst Ratings
The average analyst rating for Fate Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 4 | 4 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +284.62% | Oct 31, 2025 |
| Wedbush | Wedbush | Hold → Buy Upgrades $5 → $7 | Hold → Buy | Upgrades | $5 → $7 | +438.46% | Oct 27, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Oct 27, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $4 → $2.5 | Hold | Maintains | $4 → $2.5 | +92.31% | Aug 13, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 12, 2025 |
Financial Forecast
Revenue This Year
5.63M
from 6.65M
Decreased by -15.36%
Revenue Next Year
4.96M
from 5.63M
Decreased by -11.89%
EPS This Year
-1.17
from -1.15
EPS Next Year
-1.14
from -1.17
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.5M | 10.5M | ||||||
| Avg | 5.6M | 5.0M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 58.0% | 86.7% | ||||||
| Avg | -15.4% | -11.9% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.02 | -0.85 | ||||||
| Avg | -1.17 | -1.14 | ||||||
| Low | -1.28 | -1.41 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.